A Single-center, Double-blind, Placebo-controlled, Randomized Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-dose ACT-541468 in Healthy Japanese and Caucasian Subjects
Phase of Trial: Phase I
Latest Information Update: 02 May 2017
At a glance
- Drugs ACT 541468 (Primary)
- Indications Insomnia
- Focus Pharmacokinetics
- Sponsors Actelion Pharmaceuticals
- 26 Apr 2017 Status changed from active, no longer recruiting to completed.
- 21 Apr 2017 Planned End Date changed from 7 May 2017 to 26 Apr 2017.
- 21 Apr 2017 Planned primary completion date changed from 7 May 2017 to 24 Apr 2017.